Florida State University Research Foundation, Inc.

The United States Government as Represented by the Department of Veterans Affairs

Emilie Viennois

Binghe Wang

Xingyue Ji

Chaofeng Dai

Didier Merlin

Yueqin Zheng

Krishna Damera

Alexander Draganov

Danzhu Wang

Jitto Titus

A G Unil Perera

Merlin Didier

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37&#xb0; C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Carbon monoxide-releasing molecules for therapeutic applications and methods for the preparation and use thereof

Disclosed are methods, systems, and apparatuses for non-invasive detection of colitis in a subject. The methods involve depositing a bodily fluid sample from the subject on an internal reflection element (IRE). A beam of infrared (IR) radiation can then be directed through the IRE under conditions such that the IR radiation interacts with the bodily fluid sample. An absorption spectrum can then be recorded over a range of preselected frequencies to detect peaks that are affected by colitis. In preferred embodiments, the methods and systems involve Fourier Transform Infrared Spectroscopy (FTIR).

ATR-FTIR for non-invasive detection of colitis

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37 C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof

Growing community of inventors

Atlanta, GA, United States of America

Emilie Viennois